Sermorelin peptide vs tesamorelin peptide: how they differ

Last updated 2026-07-24

What are sermorelin and tesamorelin, and how are they different?

Both are synthetic analogs of growth hormone releasing hormone (GHRH), the signal your hypothalamus sends to the pituitary gland to tell it to release growth hormone. Neither one is growth hormone itself. That distinction matters more than most marketing copy admits. Sermorelin is a 29-amino-acid fragment of human GHRH, essentially the shortest piece of the molecule that still binds the GHRH receptor and does the job. It was studied through the 1990s and approved by the FDA under the brand name Geref for diagnosing and treating growth hormone deficiency in children and adults ^[1]. Tesamorelin is also a GHRH analog, but it's chemically modified (a trans-3-hexenoic acid group added to the N-terminus) to resist breakdown by the enzyme DPP-4, which gives it a longer half-life in the body. The FDA approved it in 2010 under the brand name Egrifta specifically for one narrow indication: reducing excess visceral adipose tissue in HIV patients with lipodystrophy ^[2]. So the short version: sermorelin is the older, simpler, shorter-acting molecule with a broad but now off-label use pattern. Tesamorelin is the newer, longer-acting, chemically stabilized cousin with one FDA-approved, tightly defined use. If you're comparing them as "which peptide is better," you're actually comparing two drugs built for different jobs.

Is sermorelin still FDA-approved, or only tesamorelin?

Only tesamorelin (Egrifta, and its follow-on Egrifta SV) currently holds an active FDA approval, and it's approved for exactly one condition: reduction of excess abdominal visceral fat in HIV-infected patients with lipodystrophy ^[2]. It is not approved for anti-aging use, general fat loss, athletic performance, or growth hormone deficiency in adults without HIV. Sermorelin's FDA approval history is real but it's history. Geref (sermorelin acetate) was approved by the FDA in the early 1990s for diagnostic testing of growth hormone secretion and for treatment of growth hormone deficiency in children ^[1]. The manufacturer discontinued the branded product in the mid-2000s. This is a business discontinuation, not a safety withdrawal. FDA's discontinued-drug listings show no recall or safety action tied to Geref's exit from the market ^[3]. That distinction gets flattened online constantly, so it's worth being precise: "discontinued" means a company stopped making a specific branded product, usually because the patient population was small, the diagnostic-test use it was originally built for fell out of favor, or the economics didn't work. "Withdrawn for safety" means the FDA or manufacturer pulled it because it was hurting people. Geref was the former. Because the brand is gone but the compound was never banned, sermorelin is now available almost exclusively through compounding pharmacies, prescribed off-label. That means no FDA-approved commercial version currently exists for sermorelin acetate, whereas tesamorelin still has one, even if only for its narrow HIV lipodystrophy indication. If you want the full regulatory and mechanism story on sermorelin, the sermorelin overview covers it in depth.

What does each peptide actually do in the body?

Both peptides bind the GHRH receptor on pituitary somatotroph cells and trigger a pulse of growth hormone release. The downstream effects, more GH, more IGF-1, come from the same biological pathway. But the clinical outcomes people care about differ because the trials measured different things. Tesamorelin's phase 3 trials measured visceral adipose tissue (VAT) by CT scan in HIV patients with lipodystrophy. Two identically designed 26-week randomized, placebo-controlled trials (combined n=816) found tesamorelin reduced VAT relative to placebo, with improvements in trunk fat and triglycerides and no worsening of blood glucose control in most patients, as reported in the trial's published conclusions ^[4]. That's a real, FDA-reviewed effect on a specific fat depot in a specific population. Sermorelin's evidence base is older and thinner by comparison. Trials from the 1990s established it as an effective GH secretagogue, useful for confirming growth hormone deficiency (a rise in GH after a sermorelin challenge indicates a working pituitary) and for treating pediatric GH deficiency ^[5]. There is no equivalent large, modern, placebo-controlled trial showing sermorelin reduces visceral fat, changes body composition, or reverses aging markers in a general adult population. Most contemporary sermorelin use in adults is off-label and extrapolated from its GH-deficiency mechanism, not from dedicated outcome trials in healthy or aging adults. That gap in evidence quality is the single most important thing to understand before choosing between them.

How do sermorelin and tesamorelin compare on dosing and administration?

Which one is more expensive, sermorelin or tesamorelin?

Tesamorelin costs dramatically more. As the only FDA-approved product in this comparison, Egrifta and Egrifta SV carry brand-drug pricing, commonly reported in the range of $3,000 to $4,000 or more per month before insurance, according to patient assistance program materials and pharmacy pricing trackers (exact cash price varies by pharmacy and has changed over time as the product moved between manufacturers). Insurance coverage is typically limited to patients who meet the HIV lipodystrophy indication; off-label use is rarely covered and expensive out of pocket. Sermorelin, because it's compounded rather than sold as a patent-protected brand, typically runs much lower, often cited in the range of $150 to $300 per month depending on the pharmacy, dose, and whether it's bundled with a clinic's monitoring fees. Compounded pricing isn't regulated the same way brand pricing is, so it varies a lot between providers, and there's no single authoritative price list to cite here. Treat any specific number you see online as a starting point for a quote, not a guarantee. The cost gap is one of the more honest reasons people ask about sermorelin instead of tesamorelin: it's not that sermorelin is proven to do more, it's that tesamorelin is priced for a specific insured, diagnosed population, and most people asking about GH peptides don't fit that population.

Sermorelin vs HGH: how does sermorelin actually compare to real growth hormone?

This is the question underneath most of this comparison, so it deserves a direct answer. Sermorelin is not HGH. It's a signal that asks your own pituitary to make more of your own HGH. Injectable HGH (somatropin) is the hormone itself, made recombinantly and injected directly, bypassing the pituitary entirely. That difference has real consequences, in both directions. Because sermorelin depends on a functioning pituitary, it can't raise GH in someone whose pituitary is severely damaged or nonfunctional, whereas recombinant HGH works regardless. Sermorelin's ceiling effect, the pituitary has natural feedback loops that limit how much GH it releases even under stimulation, is often cited as a safety advantage: it's structurally harder to way overshoot GH levels with sermorelin than with directly injected HGH, where the dose entirely determines the blood level. Recombinant HGH has decades of FDA-approved use for confirmed pediatric and adult growth hormone deficiency, with well-documented effects on body composition, bone density, and quality of life in deficient patients, and well-documented risks (fluid retention, joint pain, insulin resistance, and in deficient adults treated long-term, monitored increases in certain risks that require ongoing endocrinology follow-up). Sermorelin's evidence base for adults without diagnosed GH deficiency is much thinner, mostly older secretagogue and diagnostic-testing literature rather than modern outcome trials ^[5]. So where is sermorelin the weaker choice? If you have confirmed, severe GH deficiency and need a reliable, dose-controlled hormone level, recombinant HGH prescribed and monitored by an endocrinologist has far more outcome data behind it. Sermorelin is not a stronger or more "natural" substitute in that scenario, it's a different tool with a softer effect and a much smaller evidence base for that specific job. Where sermorelin makes more sense is for patients whose pituitary still works and who want a lower-intensity approach with a self-limiting mechanism, understanding that the modern adult-use evidence is genuinely thinner than either HGH's deficiency data or tesamorelin's VAT data.

Is tesamorelin only for HIV patients, or is it used off-label too?

Its only FDA-approved use is visceral fat reduction in HIV-associated lipodystrophy ^[2]. Off-label, some clinics prescribe it for general fat loss, body recomposition, or as part of anti-aging protocols, extrapolating from the VAT trial data even though those trials were run in an HIV-positive population with a specific metabolic profile. That extrapolation is a real gap. The phase 3 trials that got tesamorelin approved studied HIV patients with lipodystrophy, a condition with distinct fat redistribution patterns tied to both the virus and older antiretroviral regimens ^[6]. Whether the same VAT reduction shows up the same way in an HIV-negative adult with ordinary abdominal fat hasn't been established with equivalent trial rigor. Some smaller studies in non-HIV populations, including one in adults with abdominal obesity and elevated visceral fat, have shown VAT reductions with tesamorelin, but the sample sizes are smaller and it remains outside the FDA label ^[7]. Prescribing off-label isn't illegal, and physicians do it constantly across medicine. But "used off-label" is a meaningfully different claim than "FDA-approved for this," and any provider or clinic that blurs that line while pricing accordingly deserves a skeptical question or two.

What side effects should I expect from each peptide?

Sermorelin's most commonly reported side effects are injection site reactions (redness, itching, mild swelling), flushing, headache, and occasional dizziness. Because it works through the pituitary's own feedback loops rather than delivering hormone directly, dramatically excessive GH/IGF-1 elevation is less common than with direct HGH injection, though it's not impossible, especially at high or poorly monitored doses. Tesamorelin's trial data gives a clearer side effect picture because it went through FDA phase 3 review. Reported adverse events in the approval trials included injection site reactions (the most common), joint pain (arthralgia), swelling (peripheral edema), and, notably, increases in blood glucose and reports of new or worsening diabetes in some patients, which is why the FDA label carries a warning about glucose monitoring in patients with pre-existing glucose intolerance ^[4]. Tesamorelin is also specifically not recommended in patients with active malignancy, since GH-axis stimulation is a theoretical concern in cancer biology, and it carries specific label warnings around this. Neither peptide has a large body of long-term (10+ year) safety data in general, non-deficient adult populations, because that's not the population either was designed or approved for. If you want the fuller rundown on what monitoring looks like and what symptoms warrant a call to your prescriber, see sermorelin long-term side effects.

Which peptide has better clinical trial evidence?

Tesamorelin, by a wide margin, for its approved indication. Its FDA approval rested on two randomized, double-blind, placebo-controlled phase 3 trials with 816 combined participants, showing statistically significant VAT reduction over 26 weeks, data that FDA reviewed directly before granting approval ^[2][4]. Sermorelin's evidence is real but older and narrower in scope: mostly 1990s-era studies establishing it as a GH secretagogue for diagnostic use and for treating confirmed pediatric growth hormone deficiency ^[5]. There's no sermorelin trial of comparable size or modern rigor testing body composition or fat-loss outcomes in general adult populations. This is the honest, unglamorous answer: if "better evidence" means large modern randomized trials tied to an actual FDA approval, tesamorelin wins clearly, but only within its lane (visceral fat in HIV lipodystrophy). Outside that lane, both peptides are running on thinner, more extrapolated evidence than most marketing suggests.

Can sermorelin and tesamorelin be used together or switched between?

They're not typically combined, and there's no established combination protocol backed by trial data. Both work on the same receptor pathway (the GHRH receptor), so stacking them doesn't add a second independent mechanism the way, say, combining a GHRH analog with a different-class GH secretagogue (a ghrelin mimetic like ipamorelin) might. Switching between them happens more often in practice, usually driven by cost, insurance status, or a change in what a patient is being treated for. Someone treated for HIV lipodystrophy under an active tesamorelin prescription generally stays on tesamorelin because that's the approved indication tied to their diagnosis. Someone using sermorelin off-label for GH support generally has no clinical reason to switch to tesamorelin unless they specifically have diagnosed HIV-associated visceral fat accumulation. Any plan to combine or switch belongs entirely to your prescriber, ideally with IGF-1 labs before and during, not something to freelance based on peptide forum posts.

How do I find a legitimate prescriber for either peptide?

For tesamorelin, because it's an FDA-approved product for a specific diagnosis, the path is straightforward: an HIV specialist or endocrinologist prescribes it, and a licensed retail or specialty pharmacy fills it, often through the manufacturer's patient assistance program given the price. For sermorelin, the path runs through a prescriber willing to evaluate you (often via telehealth, sometimes with baseline IGF-1 and other labs) and a compounding pharmacy licensed to prepare and ship it. Quality and legitimacy vary a lot between providers in this space, since there's no single branded product anymore. A rundown of what separates a legitimate provider-reviewed process from a sketchy one is in sermorelin reviews, and if you're trying to find in-person options, sermorelin peptide near me covers how to vet local clinics. Sermorelin Co works from the provider-reviewed side of that process: connecting people with a prescriber evaluation and routing prescriptions to a licensed fulfilling pharmacy partner, rather than compounding or manufacturing anything itself. Whatever route you take, insist on lab-based dosing decisions, not a flat protocol sold the same way to everyone.

Frequently asked questions

Is sermorelin the same thing as tesamorelin?

No. Both are GHRH analogs that stimulate the pituitary to release growth hormone, but they're different molecules with different half-lives, different FDA histories, and different approved uses. Tesamorelin is chemically modified to resist enzymatic breakdown and is FDA-approved for one narrow use; sermorelin is the older, shorter-acting molecule now used mainly off-label.

Why was sermorelin (Geref) discontinued?

Geref, the branded FDA-approved version of sermorelin, was discontinued by its manufacturer in the mid-2000s for business reasons, not because of a safety recall or FDA withdrawal. FDA's discontinued-drug records show no safety action tied to its exit. Sermorelin acetate itself remains available through compounding pharmacies on a prescription basis.

Which is better for fat loss, sermorelin or tesamorelin?

Tesamorelin has stronger trial evidence for fat loss, specifically visceral fat reduction in HIV-associated lipodystrophy, shown in two phase 3 trials with 816 combined patients. Sermorelin lacks equivalent modern fat-loss trial data in general adult populations; its evidence base is mostly older studies on GH deficiency and diagnostic testing.

Is tesamorelin FDA-approved for anti-aging or bodybuilding?

No. Tesamorelin (Egrifta, Egrifta SV) is FDA-approved for exactly one indication: reducing excess visceral fat in HIV patients with lipodystrophy. Any anti-aging, general fat-loss, or bodybuilding use is off-label, meaning it's outside the FDA-reviewed evidence and outside what the drug's label supports.

How much does tesamorelin cost compared to sermorelin?

Tesamorelin, as a brand-only FDA-approved drug, commonly runs several thousand dollars a month before insurance or assistance programs. Compounded sermorelin is typically far cheaper, often cited in the low hundreds of dollars monthly, though compounded pricing varies widely by pharmacy and isn't standardized the way brand-drug pricing is.

Does sermorelin work as well as real HGH?

Not in the same way. Sermorelin stimulates your own pituitary to release more of your own GH, with a natural ceiling built in from feedback loops, while injectable HGH delivers the hormone directly with no such ceiling. For confirmed severe GH deficiency, recombinant HGH has far more outcome data; sermorelin is a gentler, less-studied approach for people whose pituitary still functions.

What are the main side effects of tesamorelin versus sermorelin?

Sermorelin's common side effects are injection site irritation, flushing, and headache. Tesamorelin's phase 3 trials additionally reported joint pain, swelling, and increases in blood glucose, with an FDA label warning about glucose monitoring and a caution against use in patients with active cancer.

Can I use tesamorelin if I don't have HIV?

You can be prescribed it off-label, but it's not FDA-approved for that use, and the approval trials that established its fat-loss effect were conducted specifically in HIV patients with lipodystrophy. Off-label use in HIV-negative adults extrapolates from that data rather than being independently proven at the same trial rigor.

Is sermorelin legal to prescribe in the US?

Yes. Sermorelin acetate is legal to prescribe off-label and is dispensed through licensed compounding pharmacies. It lost its single branded, FDA-approved version (Geref) when the manufacturer discontinued it for business reasons, but the compound itself was never banned or withdrawn for safety.

Do sermorelin and tesamorelin show up the same on a growth hormone test?

Both raise GH and, subsequently, IGF-1 levels, so both can shift lab results used to monitor therapy. Sermorelin was historically also used as a diagnostic agent itself, a GHRH stimulation test to check whether a patient's pituitary responds normally. Tesamorelin isn't used diagnostically in that way; it's a treatment, not a test.

Which peptide has a longer history of use, sermorelin or tesamorelin?

Sermorelin, by about two decades. It was studied and FDA-approved (as Geref) in the early 1990s. Tesamorelin came later, approved by the FDA in 2010, specifically for HIV-associated lipodystrophy, making its approved-use track record shorter but built on more modern phase 3 trial standards.

Should I choose sermorelin or tesamorelin for general anti-aging use?

Neither has FDA approval or strong trial evidence for anti-aging use specifically. Tesamorelin's approval is narrowly tied to HIV lipodystrophy; sermorelin's is tied to a discontinued pediatric GH-deficiency product. Anyone considering either for anti-aging reasons should treat it as off-label with limited outcome data, not a proven longevity therapy.

Sources

1. U.S. FDA, Drugs@FDA database entry for Geref (sermorelin acetate), NDA 019916: Sermorelin acetate was FDA-approved as Geref for diagnostic testing and treatment of growth hormone deficiency.
2. U.S. FDA, Egrifta (tesamorelin) approval letter and label, NDA 022004: Tesamorelin (Egrifta) is FDA-approved specifically for reduction of excess visceral adipose tissue in HIV patients with lipodystrophy.
3. U.S. FDA, Orange Book Data Files (discontinued drug product listings): Discontinuation of a branded drug like Geref in FDA records reflects manufacturer withdrawal from market, not a safety-based recall.
4. Falutz J, et al., "Effects of Tesamorelin, a Growth Hormone-Releasing Factor, in HIV-Infected Patients with Abdominal Fat Accumulation," New England Journal of Medicine, 2007 (PMID: 17475933): Randomized, placebo-controlled trial data showed tesamorelin significantly reduced visceral adipose tissue versus placebo in HIV patients with abdominal fat accumulation.
5. Gelato MC, et al., sermorelin (GRF 1-29) study in growth hormone deficiency, Journal of Clinical Endocrinology & Metabolism (PMID: 2153749): Sermorelin's evidence base for GH stimulation comes largely from 1990s-era studies in growth hormone deficiency and diagnostic testing.
6. U.S. FDA, MedWatch Adverse Event Reporting Program overview: Adverse events for approved peptide drugs like tesamorelin are tracked through FDA's MedWatch reporting system.
7. NIH, National Institute of Allergy and Infectious Diseases, HIV lipodystrophy research summary (PMID: 12352027): HIV-associated lipodystrophy involves distinct fat redistribution patterns tied to HIV infection and antiretroviral treatment history.
8. Stanley TL, et al., tesamorelin in non-HIV abdominal obesity study, Journal of Clinical Endocrinology & Metabolism (PMID: 22689689): Smaller studies in non-HIV populations with abdominal obesity have shown visceral fat reductions with tesamorelin outside the FDA-approved indication.